| Status | In progress |
| Technology type | Medicine |
| Decision | Selected |
| Reason for decision | Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources |
| Process | Cost Comparison Standard |
| ID number | 6350 |
Project Team
| Project lead | Jeremy Powell |
Email enquiries
- If you have any queries please email tateam2@nice.org.uk
| External Assessment Group | Centre for Reviews and Dissemination and Centre for Health Economics, University of York |
Stakeholders
| Companies sponsors | Neuraxpharm UK (ublituximab) |
| Others | Department of Health and Social Care |
| NHS England | |
| Patient carer groups | Multiple Sclerosis Society |
| Professional groups | Association of British Neurologists |
| Royal College of Physicians | |
| UK Multiple Sclerosis Specialist Nurse Association | |
| Comparator companies | Novartis Pharmaceuticals UK Ltd (ofatumumab) (confidentiality agreement signed - participating) |
| Roche Products Limited (ocrelizumab) (confidentiality agreement not signed - not participating) | |
| General commentators | All Wales Therapeutics and Toxicology Centre |
| British National Formulary | |
| Department of Health - Northern Ireland | |
| Healthcare Improvement Scotland | |
| Medicines and Healthcare products Regulatory Agency | |
| Scottish Medicines Consortium | |
| Welsh Government | |
| Welsh Health Specialised Services Committee |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 27 June 2024 | Invitation to participate |
| 11 March 2024 - 10 April 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6350 |
| 11 March 2024 | In progress. Scoping commenced. |
| 31 January 2023 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual